At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
Sugammadex +2 moredrug
Likely dose
Sugammadex 4mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
In Brief
A Phase 4 clinical trial evaluating Sugammadex, neostigmine, and 1 other intervention for Microlaryngoscopy and Rigid Bronchoscopy. Completed, enrolled 79 participants across 1 site.
Detailed Summary
Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrolaryngoscopy, Rigid Bronchoscopy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionJun 2018
Study CompletionMay 2019
TodayJul 2026
First PostedApr 12, 2017
Enrollment StartMay 4, 2017
Primary CompletionJun 22, 2018
Study CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.2 years ago
Interventions
Sugammadexdrug
receive reversal with sugammadex 4mg/kg
neostigminedrug
receive reversal with neostigmine 0.04 mg/kg
glycopyrrolatedrug
receive reversal with glycopyrrolate (0.01 mg/kg)